Peptides and Hormones: How They Interact in the Body

The endocrine system relies heavily on peptides to regulate virtually every physiological process in the body. Peptide hormones are short chains of amino acids that are synthesised by endocrine glands, released into the bloodstream, and act on distant target tissues by binding to specific cell-surface receptors.

Unlike steroid hormones, which are lipid-soluble and can cross cell membranes directly, peptide hormones are water-soluble and must bind to receptors on the outside of cells. This triggers intracellular signalling cascades — often involving second messengers such as cyclic AMP (cAMP) — that ultimately produce the biological effect.

Many of the peptides studied in research settings are either synthetic analogues of natural peptide hormones or secretagogues — compounds that stimulate the body's own production and release of specific hormones. Understanding how these peptides interact with hormonal pathways is essential for appreciating both their potential and their limitations.

It is important to note that research peptides are not approved medicines. The information presented here is educational and based on published scientific literature. Always consult a qualified healthcare professional before making decisions about hormonal health.

The growth hormone (GH) / insulin-like growth factor 1 (IGF-1) axis is one of the most extensively studied hormonal pathways in peptide research. This axis governs growth, body composition, metabolism, tissue repair, and aspects of ageing.

Naturally, the hypothalamus releases growth hormone-releasing hormone (GHRH), which stimulates the anterior pituitary gland to secrete GH. GH then travels to the liver and other tissues, where it stimulates the production of IGF-1. This cascade influences muscle growth, fat metabolism, bone density, and cellular regeneration.

CJC-1295 is a synthetic analogue of GHRH that has been modified to resist enzymatic degradation, giving it a significantly longer half-life than natural GHRH. When combined with Drug Affinity Complex (DAC), CJC-1295 can maintain elevated GH levels for days rather than minutes. Research suggests it promotes sustained, pulsatile GH release that more closely mimics natural physiology than exogenous GH injection.

Ipamorelin works through a different but complementary mechanism. It is a selective growth hormone secretagogue receptor (GHS-R) agonist — essentially mimicking the action of ghrelin at the pituitary level, but without significantly affecting cortisol or prolactin. This selectivity is what distinguishes ipamorelin from older secretagogues like GHRP-6, which tend to raise cortisol and increase appetite.

When CJC-1295 and ipamorelin are used together, they act on both sides of the GH release equation — stimulating GHRH signalling and activating the ghrelin receptor simultaneously — which research suggests produces a synergistic increase in GH output.

Glucagon-like peptide 1 (GLP-1) is an incretin hormone produced by L-cells in the small intestine in response to food intake. It plays a pivotal role in glucose homeostasis through several interconnected mechanisms.

When GLP-1 binds to its receptor on pancreatic beta cells, it enhances glucose-dependent insulin secretion. Critically, this effect is glucose-dependent — meaning GLP-1 only stimulates insulin release when blood sugar is elevated, which reduces the risk of hypoglycaemia compared to insulin injections or sulphonylureas. GLP-1 also suppresses glucagon secretion from pancreatic alpha cells, further reducing hepatic glucose output.

Beyond the pancreas, GLP-1 acts on the brain to promote satiety and reduce appetite, and it slows gastric emptying, which contributes to more stable post-meal blood glucose levels. These combined effects explain why GLP-1 receptor agonists like semaglutide have become some of the most impactful pharmaceutical peptides of the modern era.

Semaglutide (marketed as Ozempic for type 2 diabetes and Wegovy for weight management) is a synthetic GLP-1 analogue engineered with a fatty acid side chain that enables albumin binding, extending its half-life to approximately one week. This allows once-weekly dosing and produces sustained improvements in glycaemic control and body weight. The relationship between GLP-1 signalling, insulin sensitivity, and metabolic health illustrates how a single peptide pathway can have far-reaching systemic effects.

The melanocortin system is a family of peptide hormones and receptors that regulate pigmentation, energy balance, sexual function, and inflammation. It is one of the most versatile peptide-mediated signalling networks in the body.

The system centres on pro-opiomelanocortin (POMC), a precursor peptide that is cleaved into several active fragments, including alpha-melanocyte-stimulating hormone (α-MSH), adrenocorticotropic hormone (ACTH), and beta-endorphin. These fragments act on five melanocortin receptors (MC1R through MC5R), each mediating different physiological effects.

MC1R primarily controls skin and hair pigmentation. Activation of MC1R by α-MSH stimulates melanogenesis — the production of melanin. This is the pathway targeted by Melanotan II, a synthetic analogue of α-MSH that has been studied for its tanning and photoprotective effects, though it is not an approved medicine and carries significant safety considerations.

MC4R plays a central role in energy homeostasis and sexual function. Activation of MC4R in the hypothalamus suppresses appetite and increases energy expenditure. It also facilitates sexual arousal pathways, which is the mechanism behind PT-141 (bremelanotide), a melanocortin agonist that has been approved in some jurisdictions for hypoactive sexual desire disorder. The interplay between melanocortin signalling, appetite regulation, and reproductive function demonstrates how intimately connected these hormonal systems are.

The hypothalamic-pituitary-gonadal (HPG) axis governs reproductive hormone production and fertility in both men and women. Several peptides play critical regulatory roles within this axis.

At the top of the cascade, gonadotropin-releasing hormone (GnRH) is a decapeptide secreted by the hypothalamus in a pulsatile manner. GnRH stimulates the anterior pituitary to release luteinising hormone (LH) and follicle-stimulating hormone (FSH), which in turn act on the gonads to stimulate testosterone or oestrogen production and support gametogenesis.

Kisspeptin-10 is a peptide that has attracted considerable research interest for its role as an upstream regulator of GnRH. Kisspeptin neurons in the hypothalamus act as a "master switch" for the HPG axis — they integrate metabolic, circadian, and stress signals and determine whether GnRH is released. Research has demonstrated that kisspeptin administration can restore pulsatile GnRH secretion in individuals with hypothalamic amenorrhoea and may improve outcomes in assisted reproduction protocols.

Ghrelin, while primarily known as the "hunger hormone," also interacts with the HPG axis. Elevated ghrelin levels (as seen during caloric restriction) can suppress GnRH pulsatility, contributing to reduced fertility during energy deficit states. This cross-talk between metabolic and reproductive peptide signalling illustrates why nutrition status directly impacts hormonal health.

Understanding these peptide-hormone interactions is essential for anyone interested in the broader implications of peptide research. However, it is vital to recognise that manipulating hormonal axes carries inherent risks, and any intervention should only be considered under the supervision of a qualified medical professional.

The hormonal pathways discussed in this article are deeply interconnected, and peptides that modulate one axis frequently have downstream effects on others. For example, growth hormone secretagogues can influence insulin sensitivity, thyroid function, and cortisol levels. GLP-1 agonists affect not only pancreatic function but also appetite signalling in the brain and cardiovascular risk markers.

This interconnectedness means that the effects of peptide interventions are rarely confined to a single system. Researchers must consider the full endocrine context when evaluating the potential benefits and risks of any peptide. For instance, excessive GH stimulation could theoretically worsen insulin resistance, while chronic GLP-1 receptor activation may affect pancreatic beta-cell mass over time — though current evidence suggests this risk is low with approved therapeutics.

From a safety perspective, several principles are worth emphasising. First, the body's hormonal systems operate through negative feedback loops — overstimulation of any pathway will often trigger compensatory downregulation. Second, individual responses to peptides vary significantly based on age, sex, baseline hormone levels, and genetic factors. Third, the long-term effects of many research peptides on human endocrine function remain incompletely characterised.

This content is provided for educational purposes only and does not constitute medical advice. Peptides discussed here (with the exception of specifically noted approved pharmaceuticals) are research compounds and are not licensed medicines in the UK. Anyone considering peptide use should consult a qualified healthcare professional who can evaluate their individual hormonal profile and medical history.